Safety and Feasibility of Romiplostim Treatment for Patients with Persistent Thrombocytopenia After Allogeneic Stem Cell Transplantation

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2015 Aug 18

PMID 26281029

Citations 7

Authors

G Battipaglia

A Ruggeri

E Brissot

A-C Mamez

F Malard

R Belhocine

A Vekhoff

F Giannotti

T Ledraa

M Labopin

M-T Rubio

M Mohty

Affiliations

Soon will be listed here.

Citing Articles

Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review.

Elsayed A, Elsayed B, Elmarasi M, Elsabagh A, Elsayed E, Elmakaty I Immunotargets Ther. 2024; 13:461-486.

PMID: 39290805 PMC: 11407319. DOI: 10.2147/ITT.S463384.

Avatrombopag for the treatment of thrombocytopenia in children's patients following allogeneic hematopoietic stem-cell transplantation: A pilot study.

Ruan Y, Cao W, Luo T, Liu X, Liu Q, Xiao Y Front Pediatr. 2023; 11:1099372.

PMID: 36873638 PMC: 9975496. DOI: 10.3389/fped.2023.1099372.

Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature.

Bortolotti M, Pettine L, Zaninoni A, Croci G, Barcellini W, Fattizzo B Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455416 PMC: 9032708. DOI: 10.3390/ph15040419.

Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation.

Bento L, Canaro M, Bastida J, Sampol A J Clin Med. 2022; 11(5).

PMID: 35268455 PMC: 8911458. DOI: 10.3390/jcm11051364.

A Review of Romiplostim Mechanism of Action and Clinical Applicability.

Bussel J, Soff G, Balduzzi A, Cooper N, Lawrence T, Semple J Drug Des Devel Ther. 2021; 15:2243-2268.

PMID: 34079225 PMC: 8165097. DOI: 10.2147/DDDT.S299591.

References

First L, Smith B, Lipton J, Nathan D, Parkman R, Rappeport J . Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood. 1985; 65(2):368-74. View

Nash R, Gooley T, Davis C, Appelbaum F . The problem of thrombocytopenia after hematopoietic stem cell transplantation. Stem Cells. 1996; 14 Suppl 1:261-73. DOI: 10.1002/stem.5530140734. View

Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S . CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 2013; 20(3):382-6. DOI: 10.1016/j.bbmt.2013.11.034. View

Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W . Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997; 336(6):404-9. DOI: 10.1056/NEJM199702063360603. View

Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L . Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant. 2003; 33(4):419-23. DOI: 10.1038/sj.bmt.1704330. View

Bruno B, Gooley T, Sullivan K, Davis C, Bensinger W, Storb R . Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(3):154-62. DOI: 10.1053/bbmt.2001.v7.pm11302549. View

Nakamae H, Storer B, Sandmaier B, Maloney D, Davis C, Corey L . Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica. 2011; 96(12):1838-45. PMC: 3232267. DOI: 10.3324/haematol.2011.044966. View

Seber A, Shu X, DeFor T, Sencer S, Ramsay N . Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant. 1999; 23(1):35-40. DOI: 10.1038/sj.bmt.1701523. View

Trotman J, Nivison-Smith I, Dodds A . Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration. Bone Marrow Transplant. 1999; 23(8):797-801. DOI: 10.1038/sj.bmt.1701644. View

10.

Dominietto A, Raiola A, Van Lint M, Lamparelli T, Gualandi F, Berisso G . Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 2001; 112(1):219-27. DOI: 10.1046/j.1365-2141.2001.02468.x. View

11.

Kantarjian H, Giles F, Greenberg P, Paquette R, Wang E, Gabrilove J . Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010; 116(17):3163-70. PMC: 3324162. DOI: 10.1182/blood-2010-03-274753. View